Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
National Cancer Institute Search for Clinical Trials
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Optimizing IFN Beta - 1B Dose (Optims)
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Pages
« first
‹ previous
…
76
77
78
79
80
81
82
83
84
…
next ›
last »